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Hippocampal integrity is essential for cognitive functions. On 
the  other  hand,  induction  of  metallothionein  (MT)  by  ZnSO4 
and its role in neuroprotection has been documented. The present 
study aimed to explore the effect of MT induction on carmustine 
(BCNU)-induced  hippocampal  cognitive  dysfunction  in  rats.  A 
total of 60 male Wistar albino rats were randomly divided into four 
groups (15/group): The control group injected with single doses 
of normal saline (i.c.v) followed 24 h later by BCNU solvent (i.v). 
The second group administered ZnSO4 (0.1 μmol/10 μl normal 
saline, i.c.v, once) then BCNU solvent (i.v) after 24 h. Third group 
received BCNU (20 mg/kg, i.v, once) 24 h after injection with 
normal saline (i.c.v). Fourth group received a single dose of ZnSO4 
(0.1 μmol/10 μl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, 
once) after 24 h. The obtained data revealed that BCNU adminis-
tration resulted in deterioration of learning and short-term memory 
(STM), as measured by using radial arm water maze, accompanied 
with decreased hippocampal glutathione reductase (GR) activity 
and  reduced  glutathione  (GSH)  content.  Also,  BCNU  admin-
istration  increased  serum  tumor  necrosis  factor-alpha  (TNFα), 
hippocampal MT and malondialdehyde (MDA) contents as well 
as caspase-3 activity in addition to histological alterations. ZnSO4 
pretreatment counteracted BCNU-induced inhibition of GR and 
depletion  of  GSH  and  resulted  in  significant  reduction  in  the 
levels of MDA and TNFα as well as the activity of caspase-3. The 
histological features were improved in hippocampus of rats treated 
with ZnSO4 + BCNU compared to only BCNU-treated animals. 
In conclusion, MT induction halts BCNU-induced hippocampal 
toxicity  as  it  prevented  GR  inhibition  and  GSH  depletion  and 
counteracted the increased levels of TNFα, MDA and caspase-3 
activity with subsequent preservation of cognition.
Introduction
It is increasingly apparent that neurological disorders including 
disruption of brain functions associated with the systemic delivery 
of chemotherapeutic agents used for treatment of central nervous 
system (CNS) and non-CNS tumors.1,2 There is a growing evidence 
that standard-dose chemotherapy can impact cognitive function.3 
Previous  studies  suggested  that  18%  of  all  breast  cancer  patients 
receiving  standard-dose  chemotherapy  show  cognitive  defects  on 
post-treatment  evaluation,4  and  such  problems  were  reported  in 
more than 30% of patients examined two years after treatment with 
high-dose chemotherapy.5,6 In addition, Vardy and Tannock7 have 
reported impaired cognitive functions during treatment of solid brain 
tumors in animal models and in humans. It has been concluded that 
administration of methotrexate and 5-FU in combination induced 
impairments in tests of spatial memory and other cognitive tasks in 
mice.8 Also, a single dose of cyclophosphamide produced a transient 
acute memory impairment in mice.9 Moreover, adriamycin has been 
demonstrated to increase oxidative stress in the brain, which may 
lead to cell dysfunction or cell death and thus contribute to cogni-
tive dysfunction.10 Furthermore, it has been reported that long-term 
exposure to 13-cis-retinoic acid, which is often used in chemotherapy 
regimens, was associated with decreased neurogenesis and cell prolif-
eration in the hippocampus and subventricular zone and impaired 
spatial learning and memory in young and adult mice.11
Vardy  et  al.12  reported  that  the  etiology  of  cognitive  impair-
ment after chemotherapy remains unknown although a number of 
mechanisms have been postulated.13 Candidate mechanisms include: 
direct  neurotoxic  effects  (e.g.,  injury  to  neurons  or  surrounding 
cells, altered neurotransmitter levels),14 oxidative stress and DNA 
damage,15  immune  dysregulation  and/or  release  of  cytokines13,16 
and blood clotting in small CNSvessels.12
Carmustine (BCNU) is an alkylating agent used in the treatment 
of brain tumors, myeloma, and both Hodgkin and non-Hodgkin 
lymphoma.17  The  ability  of  BCNU  to  cross  blood-brain  barrier 
(BBB)  may  explain  its  neurotoxicity.18  Studies  on  the  incidence 
and the mechanisms of cognitive dysfunction after BCNU admin-
istration are rare. Among these studies, Dietrich et al.17 explained 
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significant  level  in  comparison  with  ZnSO4-treated  group.  The 
group of rats pretreated with ZnSO4 then 24 hours later with BCNU 
show marked increases in the level of hippocampal MT content up 
to110%, 36.5% and 61% if compared to the control, ZnSO4-treated 
or BCNU-treated groups respectively (Fig. 1).
Immunohistochemical staining of MT in brain sections by using 
specific antibodies revealed that the level of brain MT was obviously 
increased  in  the  tested  groups  of  rats  in  the  order  of  ZnSO4-
pretreated-BCNU-treated (D) >ZnSO4-treated (B) >BCNU-treated 
(C) >control (A) groups (Fig. 2).
Learning and memory. Behavioral tests in the present study show 
that there is direct correlation between the good learning and short-
term memory (STM) of rats on one hand and the number of learning 
trials on the other hand where the number of errors were decreased 
as  the  number  of  trials  increased  in  all  tested  groups  (Fig.  3). 
BCNU administration deteriorated both learning and memory when 
compared to the corresponding control groups. However, ZnSO4 
administration before BCNU obviously improved both learning and 
memory (Fig. 3).
Statistical analysis of data (Fig. 4) explain that the group of rats 
injected with BCNU showed a markedly impaired learning behavior 
by the extents of 32% from the control group and 39% from ZnSO4-
treated group. Administration of ZnSO4 before BCNU normalized 
the decreased learning behavior (Fig. 4). Also, BCNU administration 
significantly reduced STM in rats to be 31% and 35% of control and 
ZnSO4-treated rats respectively (Fig. 5). Rats pretreated with ZnSO4 
then BCNU showed significant improvement in STM if compared 
to rats treated with BCNU without ZnSO4 preadministration as it 
was increased to reach 81% of the control group and 85% of ZnSO4-
treated rats (Fig. 5).
Glutathione  reductase  (GR)  activity  and  reduced  glutathione 
(GSH) content. The present data explain that the activity of GR 
(Fig. 6) and the level of GSH (Fig. 7) in rat hippocampus was aggres-
sively reduced by administration of BCNU to the extents of 49% and 
53% of the control group; and 47% and 51% of ZnSO4-treated rats 
that  the  cognitive  dysfunction  induced  by  the  three  widely  used 
  chemotherapy  agents  (carmustine,  cisplatin  and  cytosine  arabi-
noside) is due to their toxic effects on CNS progenitor cells and 
non-dividing oligodendrocytes in vitro.19 They also found that these 
agents caused increased cell death and decreased cell division in the 
subventricular zone, the dentate gyrus of the hippocampus and the 
corpus callosum in mice.
Metallothioneins  (MTs)  are  a  family  of  low  molecular  weight 
cysteine-rich,  proteinsthat  are  associated  with  transition  metal 
cations  including  Zn,  Cd,  Cu  and  Hg.20  Previous  studies  have 
indicated the role of MT in protecting cells, tissues and organisms 
from environmental toxicant-induced damage.21,22 Three isoforms 
of metallothioneins (MT-I, MT-II and MT-III) are expressed in the 
central nervous system.23 Previous studies reported that brain MT-I/
II are upregulated by different stressful stimuli including psycho-
genic  stress,24  administration  of  bacterial  endotoxin,25  glutamate 
analogues,26  metal  toxicity27  and  stroke/ischemia.28  In  partic-
ular  MT  I  and  II  could  protect  neuroglial  cells  from  oxidative 
damage.29 The  authors  conclude  that  lack  of  this  protection  has 
been found to potentiate excitotoxicity and neurodegeneration in 
the hippocampus.
A common feature seen in a number of studies is that MT-I, II 
reduces delayed cerebral damage and cell death, as well as promotes 
brain  repair,  angiogenesis  and  functional  recovery.30  Interestingly, 
MT-I, II were shown to act directly as neurotrophic agents after 
treatment  of  neurons  with  exogenous  MT-I,  II  proteins,  which 
enhance neuronal survival and axonal outgrowth in both cortical, 
hippocampal and dopaminergic cultures.31,32
Regulation of metallothionein gene expression by zinc has been 
documented.33 Free zinc induces the accumulation of large amount 
of  zinc-containing  metallothioneins.34  A  number  of  studies  have 
suggested that zinc status affects metallothionein concentration and 
its mRNA synthesis in the various tissues of growing and adult rats 
and mice.35 It has been reported that metallothionein induced by zinc 
exhibits protective effects on the cardiac apoptosis of doxorubicin,36 
anthracycline-induced  cardiac  toxicity37  and  adriamycin-induced 
myocardial injury.38 Increased MT expression in some tissues after 
in vivo treatment with DNA alkylating agents has been reported.39 
It was found that rat hepatocytes with elevated MT levels are resistant 
to N-methyl-N’-nitro-nitrosoguanidine cytotoxicity.40 Also, overex-
pressed human MT-IIA gene protects Chinese hamster ovary cells 
from killing by alkylating agents.34 Moreover, treatment of tumor-
bearing mice with ZnSO4 increased hepatic, renal and tumor MT 
and protected them from cytotoxic actions of cisplatin.35
However few studies have been carried out to explore the role of 
MT in neurocognitive functions,41,42 the relationship between MT 
induction and cognition deficits by chemotherapeutic agents is still 
not clear. The current study aimed to address the effect and mecha-
nism of centrally-induced MT on the impact of BCNU on learning 
and memory in rats.
Results
Brain  metallothionein  (MT).  Data  in  Figure  1  explains  that 
injection of ZnSO4 markedly increased hippocampal MT content 
(53%) when compared to the corresponding control group.  Also, 
administration  of  BCNU  significantly  increased  MT  level  in  the 
hippocampus of control rats by an extent of 29% but still at a lower 
Figure 1. Effect of ZnSO4 and/or carmustine (BCNU) on the level of hip-
pocampal metallothionein (MT) in rats. Data are presented as mean ± SEM 
(n = 10) and analyzed using Graph Pad Instat software by one way ANOVA 
followed by Tukey Kramer post-test. ZnSO4 was injected as a single dose 
(0.1 μmol/10 μl saline, i.c.v). BCNU was injected in a single dose (20 mg/
kg i.v). Animals were sacrificed after three weeks where MT was measured 
in  hippocampal  homogenates.  (a–c):  Indicate  significant  differences  from 
control, BCNU-treated and ZnSO4-pretreated-BCNU-treated groups respec-
tively at p < 0.05.Metallothionein in memory impairement
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Figure 2. A photomicrograph for immunohistochemical staining of metallothionein (MT) in hippocampal sections from control (A), ZnSO4-treated (B), BCNU-
treated (C) and ZnSO4-pretreated-BCNU-treated rats (D) shows increased MT level in the order of ZnSO4-pretreated-BCNU-treated (D) >ZnSO4-treated (B) 
>BCNU-treated (C) >control (A). ZnSO4 was injected as a single dose (0.1 μmol/10 μl saline, i.c.v). BCNU was injected in a single dose (20 mg/kg i.v). 
Staining of MT in hippocampal sections was carried out by using MT-specific antibodies and ABC detection kit.
Figure 3. Effect of single doses of ZnSO4 and/or carmustine (BCNU) on 
learning and short-term memory (STM) in rats. Raw data are presented as 
mean values (n = 15). ZnSO4 was injected as a single dose (0.1 μmol/10 μl 
saline, i.c.v). BCNU was injected in a single dose (20 mg/kg i.v). Learning 
and short-term memory (STM) were assessd by using radial arm water maze 
where the number of errors for each group was calculated in 12 trials to 
indicate learning behaviour. After 30 min from leaning phase STM for each 
group was assessed by measuring the number of errors.
Figure 4. Effect of ZnSO4 and/or carmustine (BCNU) on learning of rats. 
Data are presented as mean ± SEM (n = 10) and analyzed using Graph 
Pad Instat software by one way ANOVA followed by Tukey Kramer post-test. 
ZnSO4 was injected as a single dose (0.1 μmol/10 μl saline, i.c.v). BCNU 
was injected in a single dose (20 mg/kg i.v). Learning was assessed by 
using radial arm water maze where the number of errors for each group 
was calculated in 12 trials to indicate learning behaviour. (a–c): Indicate 
significant  differences  from  control,  BCNU-treated  and  ZnSO4-pretreated-
BCNU-treated groups respectively at p < 0.05.
respectively. Treatment of rats with ZnSO4 before BCNU resulted in 
marked increases in the activity of GR (to the extents 76% and 72% 
of the control and ZnSO4-treated groups respectively) and GSH 
content (to the extents of 73% and 71% of the control and ZnSO4-
treated groups respectively).
Malondialdehyde (MDA). In Figure 8 MDA showed 2.5 fold 
increase in the hippocampus BCNU-treated animals when compared 
to  either  control  or  ZnSO4-treated  groups.  In  the  group  of  rats 
preinjected with ZnSO4 then BCNU there was up to 60% reduc-
tion in the level of MDA compared to BCNU-treated rats but still 
at a higher level of significance in comparison with either control or 
ZnSO4-trated animals.
TNFα. Evaluation of serum TNFα revealed that BCNU produced 
significant increases in the level of TNFα up to 44% and 39% when Metallothionein in memory impairement
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compared with control or ZnSO4-trated animals respectively. On the 
other hand, this level showed a marked reduction (15%) in ZnSO4-
pretrated-BCNU-treated rats in comparison with only BCNU-treated 
animals although it was still at a significant higher level if compared to 
control or ZnSO4-trated groups (Fig. 9).
Caspase-3 enzyme activity. Figure 10 explains that the activity of 
caspase-3 enzyme was markedly increased in the hippocampus of rats 
treated with BCNU compared to either control (by 31%) or ZnSO4-
treated (by 34%) animals. In ZnSO4-pretreated-BCNU-trated rats, 
the  activity  of  caspase-3  was  significantly  decreased  to  the  extents 
of  12%  and  15%  from  of  the  control  and  ZnSO4-treated  groups   
respectively.
Figure 5. Effect of ZnSO4 and/or carmustine (BCNU) on short-term memory 
(STM) in rats. Data are presented as mean ± SEM (n = 10) and analyzed 
using Graph Pad Instat software by one way ANOVA followed by Tukey 
Kramer post-test. ZnSO4 was injected as a single dose (0.1 μmol/10 μl 
saline, i.c.v). BCNU was injected in a single dose (20 mg/kg i.v). STM was 
assessed after 30 min from leaning phase by using radial arm water maze 
where the number of errors for each group was calculated to indicate STM 
behaviour. (a–c): Indicate significant differences from control, BCNU-treated 
and ZnSO4-pretreated-BCNU-treated groups respectively at p < 0.05.
Figure 6. Effect of ZnSO4 and/or carmustine (BCNU) on hippocampal gluta-
thione reductase (GR) activity in rats. Data are presented as mean ± SEM (n 
= 10) and analyzed using Graph Pad Instat software by one way ANOVA 
followed by Tukey Kramer post-test. ZnSO4 was injected as a single dose 
(0.1 μmol/10 μl saline, i.c.v). BCNU was injected in a single dose (20 mg/
kg i.v). GR activity was assessed in hippocampal homogenates at the end 
of the experiment period (3 weeks). (a–c): Indicate significant differences 
from  control,  BCNU-treated  and  ZnSO4-pretreated-BCNU-treated  groups 
respectively at p < 0.05.
Figure 7. Effect of ZnSO4 and/or carmustine (BCNU) on the level of reduced 
glutathione (GSH) in the hippocampus of rats. Data are presented as mean 
± SEM (n = 10) and analyzed using Graph Pad Instat software by one way 
ANOVA followed by Tukey Kramer post-test. ZnSO4 was injected as a single 
dose (0.1 μmol/10 μl saline, i.c.v). BCNU was injected in a single dose (20 
mg/kg i.v). GSH content was assessed in hippocampal homogenates at the 
end of the experiment period (3 weeks). (a–c): Indicate significant differences 
from  control,  BCNU-treated  and  ZnSO4-pretreated-BCNU-treated  groups 
respectively at p < 0.05.
Figure 8. Effect of ZnSO4 and/or carmustine (BCNU) on the level of malon-
dialdehyde (MDA) in the hippocampus of rats. Data are presented as mean 
± SEM (n = 10) and analyzed using Graph Pad Instat software by one way 
ANOVA followed by Tukey Kramer post-test. ZnSO4 was injected as a single 
dose (0.1 μmol/10 μl saline, i.c.v). BCNU was injected in a single dose 
(20 mg/kg i.v). MDA content was assessed in hippocampal homogenates 
at the end of the experiment period (three weeks). (a–c): Indicate significant 
differences from control, BCNU-treated and ZnSO4-pretreated-BCNU-treated 
groups respectively at p < 0.05.
Histological examination. Figure 11 explains that administration 
of  BCNU  resulted  in  massive  neuronal  damage  manifested  as  an 
apparent decrease (45%) in the number of normal-appearing neurons 
in the middle hippocampus CA1 in which most pyramidal cells died 
(Fig. 11C) compared with either control (Fig. 11A) or ZnSO4-treated 
animals (Fig. 11B). Animals pretreated with ZnSO4 and 24 hours 
later  with  BCNU  (Fig.  11D)  showed  an  obvious  increase  (30%) 
in  the  number  of  intact  neurons  as  compared  to  BCNU-treated 
animals. A photomicrograph of rat brain sections stained with Hx & 
E (X 40) shows CA1 region of the hippocampus from control (A), 
ZnSO4-treated (B), BCNU-treated rats (C) and ZnSO4-pretreated-
BCNU-treated rats (D).Metallothionein in memory impairement
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dysfunction in experimental animals.10 In addition, exposure to13-
cis-retinoic acid, impaired spatial learning and memory in mice.11 
Moreover, the present data are in close agreement with the study of 
Dietrich et al.17 who reported cognitive dysfunction after administra-
tion of carmustine, cisplatin and cytosine arabinoside in mice.
The  relationship  between  the  integrity  of  hippocampus  and 
normal learning and memory pattern has been documented.17 The 
present study showed that BCNU induced oxidative stress in the 
hippocampus of rats as indicted by aggressive inhibition of GR enzyme 
Figure 9. Effect of ZnSO4 and/or carmustine (BCNU) on the level of reduced 
tumour necrosis factor-alpha (TNFα) in the serum of rats. Data are presented 
as mean ± SEM (n = 10) and analyzed using Graph Pad Instat software by 
one way ANOVA followed by Tukey Kramer post-test. ZnSO4 was injected 
as a single dose (0.1 μmol/10 μl saline, i.c.v). BCNU was injected in a 
single dose (20 mg/kg i.v). TNFα level was assessed in the serum at the end 
of the experiment period (3 weeks). (a–c): Indicate significant differences 
from  control,  BCNU-treated  and  ZnSO4-pretreated-BCNU-treated  groups 
respectively at p < 0.05.
Figure 10. Effect of ZnSO4 and/or carmustine (BCNU) on the activity of 
caspase-3 enzyme in the hippocampus of rats. Data are presented as mean 
± SEM (n = 10) and analyzed using Graph Pad Instat software by one way 
ANOVA followed by Tukey Kramer post-test. ZnSO4 was injected as a single 
dose (0.1 μmol/10 μl saline, i.c.v). BCNU was injected in a single dose (20 
mg/kg i.v). Caspase-3 activity was assessed in hippocampal homogenates 
at the end of the experiment period (3 weeks). (a–c): Indicate significant 
differences from control, BCNU-treated and ZnSO4-pretreated-BCNU-treated 
groups respectively at p < 0.05.
Figure  11.  A  photomicrograph  of 
rat  brain  sections  stained  with  Hx 
&  E  (X  40)  shows  CA1  region  of 
the  hippocampus  from  control  (A), 
ZnSO4-treated (B), BCNU-treated rats 
(C)  and  ZnSO4-pretreated-BCNU-
treated  rats  (D)  explains  that  admin-
istration of BCNU resulted in massive 
neuronal  damage  manifested  as  a 
decrease  (45%)  in  the  number  of 
normal-appearing  neurons  (as  cal-
culated  as  mean  number/10  fields) 
in  the  middle  hippocampus  CA1  in 
which most pyramidal cells died (C) 
compared  with  either  control  (A)  or 
ZnSO4-treated  animals  (B).  Animals 
pretreated with ZnSO4 and 24 hours 
later with BCNU (D) shows an obvi-
ous increase (30%) in the number of 
intact neurons as compared to BCNU-
treated animals. ZnSO4 was injected 
as  a  single  dose  (0.1  μmol/10  μl 
saline, i.c.v). BCNU was injected in a 
single dose (20 mg/kg i.v).
Discussion
Impaired cognitive functions after administration of chemothera-
peutic agents have been reported in animal models and in humans.7 
The present data revealed that injection of BCNU into rats resulted 
in impairment of learning and STM. This effect is in consistence with 
the previous study of Reiriz et al.9 who reported that a single dose 
of cyclophosphamide produced a transient acute memory impair-
ment in mice. Also, it was found that adriamycin produced cognitive Metallothionein in memory impairement
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agents, inflammation and stress.22 The induced MT in response to 
BCNU administration is in harmony with the reported role of MT 
in resistance to alkylating agents during treatment of cancers such 
as  bladder  cancer55  and  esophageal  cancer.56  Also,  recent  studies 
strongly suggested a significant role of MT during neurodegenera-
tive diseases and in response to brain injury.57 In addition, Schroder 
et al.39 have considered that tissue induction of MT as a mecha-
nism of resistance to oxidative stress produced by alkylating agents. 
Therefore, the increased level of MT in BCNU-treated animals may 
represents an acute phase response to act against increased oxidative 
stress produced by BCNU.
It has been stated that, metal-induced synthesis of MT is mediated 
by activation of metal response element-binding transcription factor 
(MTF-1), a zinc-sensitive trans-acting factor.57,58 The increased level 
of MT after ZnSO4 injection in the present work is in close agree-
ment with the early study of Ebadi and Swanson59 who found that 
i.c.v injection of zinc induced brain MT. In addition, several studies 
have suggested that zinc status affects metallothionein concentration 
and its mRNA synthesis in the various tissues of growing and adult 
rats and mice.60 Recently, it has concluded that administration of 
Zn2+ (i.v) during reperfusion phase of cerebral ischemia could pass 
BBB and induced hippocampal MT.28
Although MT has been documented to protect against neuronal 
injury,61  its  role  in  neurobehavioral  function  have  not  been  well 
characterized.57 Behavioral tests in the present study showed marked 
potentiation of learning and memory in rats pretreated with ZnSO4 
(i.c.v), 24 hours before BCNU, compared to those without ZnSO4 
preadministration. These data may explain the decisive role of MT 
induction in the improvement of cognition during BCNU admin-
istration. In this respect, West et al.57 believed that alterations in 
MT function could alter neural function in ways that would impair 
behavioral function. The authors explained that MTs play a signifi-
cant role in zinc homeostasis in the hippocampus which is essential 
in maintenance of normal cognitive functions. Also, it was concluded 
that the hippocampus, which plays a central role in cognitive func-
tions  such  as  memory  depends  on  correct  physiological  actions 
of zinc, which is heavily concentrated in the hippocampal mossy 
fiber system.41 In addition, MT-I/II were found to protect against 
the adverse effects of both zinc under and overload.62 Moreover, 
  metallothionein-null mice showed learning deficits in passive avoid-
ance and water maze escape learning.63
The obtained data revealed that pretreatment of rats with ZnSO4 
(i.c.v)  before  BCNU  conferred  protection  of  the  hippocampus 
against BCNU-induced damage as the levels of caspase-3 and MDA 
were markedly reduced but the contents of MT and GSH as well as 
the activity of GR in the hippocampus were significantly higher if 
compared to only BCNU-treated rats. Also, serum TNFα showed 
apparent  reduction  in  rats  preinjected  with  ZnSO4. This  protec-
tion  was  further  confirmed  by  histological  examination.  These 
data are in line with the previous studies in which neuronal injury 
was reported to be implicated in cognitive dysfunction.17 On the 
other hand, MT-I, II were shown to enhance neuronal survival and 
axonal outgrowth in both cortical, hippocampal and dopaminergic 
cultures.30,32 In addition, MT was found to protect against neuronal 
damage via its powerful antioxidant and antiapoptic properties.9,64 
Moreover, MT counteracted oxidative stress and apoptosis in animals 
treated with DNA alkylating agents.39 Furthermore, treatment of 
activity,  reduction  of  GSH  content  and  increased  hippocampal 
content of MDA in comparison with the control groups. In addi-
tion, serum TNFα and the activity of caspase-3 showed significant 
higher hippocampal levels in BCNU-treated animals compared to 
corresponding  control  values.  Moreover,  microscopic  examination 
of hippocampal sections showed deteriorated histological features in 
rats treated with BCNU if compared to control groups. These data 
are in harmony with the previous investigations that reported BCNU 
as a potent GR inhibitor and GSH depletor in several tissues.43,44   
It has been explained that depletion of GSH, as a consequence of GR 
inhibition will increase cellular oxidative damage.45
The  increased  extent  of  lipid  peroxidation  and  apoptosis  (as 
indicated  by  increased  caspase-3  activity)  in  the  hippocampus  as 
well as the level of serum TNFα after BCNU administration in the 
present study is supported by previous studies on various tissues. In 
this respect, it was found that incubation of BCNU with rat brain 
slices for two hours produced marked depletion of GSH (up to 70%) 
accompanied with increased extent of lipid peroxides.46 Also, BCNU 
was found to inhibit the activity of GR and promoted the oxidative 
damage  in  the  nigrostriatal  system.47  In  addition,  BCNU  could 
inhibit GR, depleted GSH and induced apoptosis in PC12 cells.48 
It has been reported that BCNU administration, as one of common 
breast cancer regimen, resulted in apparent inhibition of lung GR 
activity and GSH content with increased levels of TNFα and lipid 
peroxidation  with  marked  histological  alterations.49  Moreover, 
the interrelation between oxidative stress and release of inflamma-
tory cytokines including TNFα and subsequent tissue damage has 
been proved.50 GSH depletion was reported to be associated with 
augmentation of an oxidative stress-mediated proinflammatory state 
in alveolar epithelial cells by an oxidative stress-dependent mecha-
nism.51 Recently, it has been concluded that BCNU induced lung 
fibrosis in rats, an effect mediated by increased oxidative stress and 
induction of the proinflammatory cytokine TNFα.52 On the other 
hand, Ali-Osman et al.53 explained that, BCNU metabolites are very 
reactive electrophiles capable of depleting GSH and inducing apop-
tosis. It was also stated that the cognitive dysfunction induced by the 
three widely used chemotherapy agents (carmustine, cisplatin and 
cytosine arabinoside) is due to their toxic effects on CNS progenitor 
cells and nondividing oligodendrocytes of in vitro.19 In addition, 
BCNU was found to increased cell death and decreased cell division 
in the hippocampus of mice.17 Since neurotoxicity, DNA damage, 
Oxidative stress and release of cytokines were reported as mechanisms 
of impairment of cognitive functions after chemotherapy,12 it could 
be suggested that BCNU administration resulted in hippocampal 
toxicity in the form of apoptosis, increased level of lipid peroxidation 
and histological alterations with subsequent impairment of learning 
and memory.
The involvement of MT in protection against various stress insults 
has  been  reported.33,39,54  Imuunohistochemical  and  biochemical 
techniques in the present study showed that BCNU administration 
markedly increased the level of MT in the hippocampus of rats. Also, 
i.c.v injection of ZnSO4 into either control animals or 24 hours 
before administration of BCNU resulted in significant increase in 
the level of MT in the hippocampus of both groups in the order of 
BCNU-ZnSO4-pretreated >control. It is generally accepted that the 
expression of MT-I/II proteins is highly inducible in response to a 
range of stimuli, including metals, hormones, cytokines, oxidative Metallothionein in memory impairement
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injection (i.c.v) of normal saline (10 μl). Fourth group received a single 
dose of ZnSO4 (0.1 μmol/ 10 μl normal saline, i.c.v) followed 24 h 
later  with  an  injection  of  BCNU  (20  mg/kg,  i.v).  After  three 
weeks, animals in all groups were subjected to behavioral tests for 
learning  and  short-term  (STM)  memory  using  radial  arm  water 
maze then anaesthetized with ether and sacrificed where five rats 
from each group were used for histological analysis. The remaining 
ten rats were used for biochemical analysis where BCNU toxicity 
was evaluated by measuring MDA (as a marker for lipid peroxida-
tion), caspase-3 activity (as a marker for apoptosis) as well as the 
possible mechanisms for this toxicity by measuring GR activity and 
GSH content in the hippocampus as well as serum TNFα level. 
The  ability  of  MT  to  counteract  BCNU-induced  hippocampal 
toxicity was evaluated by measuring the previous parameters after 
MT induction by ZnSO4. In each group, blood samples from each 
animal were collected separately, centrifuged and used for determi-
nation of TNFα. The two lobes of hippocampus in each animal 
were rapidly dissected out on ice, washed with saline and cut into 
small pieces and used for biochemical analysis. Hippocampal pieces 
from each animal in each group were homogenized and used for 
determination of the activity of hippocampal glutathione reductase 
(GR) and the contents of MT, reduced glutathione (GSH), malodi-
aldehyde (MDA) as well as total protein. Another portion of pieced 
was dissociated into free cells by trypsinization where the activity of 
caspase-3 was assessed in the cell lysate.
Intracerebroventricular  (i.c.v)  injection  of  ZnSO4.  Rats  were 
anaesthetized by administration of sodium pentobarbital (60 mg/kg, 
i.p) then placed gently in a stereotaxic apparatus68 with the tooth bar 
5 mm above the ear bar. Sagittal incision was made and the scalp was 
exposed. By using brain map and stereotaxic coordinates, the bony 
calcaneum was penetrated with dental drill to allow access into the 
brain. ZnSO4 solution was slowly infused using Hamilton microsy-
ringe where the syrnge was left in place for 5 min. After removal of 
the syringe, the wounds were sutured.
The radial arm water maze procedure. The radial arm water maze 
consisted of a black circular water tub with six V-shaped stainless 
steel structures arranged to form a swimming field of an open central 
area and six arms.69 The water temperatures was maintained at 25°C. 
A goal arm is one that has a black platform submerged 1cm below the 
water level. Starting from a start arm (any arm other than the goal 
arm), the rat must find the submerged platform by swimming to the 
end of the goal arm. Each rat was allowed 12 consecutive training 
trials (learning phase) followed by a short-term memory (STM) test 
trial (30 min delay periods). Rats were allowed to take rest for 5 min 
to avoid exhaustion at the end of the 6th trial. Rats were allowed   
1 min per trial to find the submerged platform. A trial ended when 
the rat located the submerged platform, where it was allowed to stay 
trial 15 sec on the platform before removal to begin the next trial in 
a different start arm. If the rat did not find the submerged platform 
in the goal arm after one min, it was guided the goal arm and allowed 
to stay on the platform for 15 sec before removal to begin the next 
trial. A correct selection occurred when the rat swam directly to the 
goal arm, while error was registered when the rat entered into an arm 
other than the goal arm. All experiments were done in dimly lit room 
and the rat had to use cues in the room to spatially memorize the 
location of the platform. After the last trial the mean umber of errors 
was calculated for each group to indicate the learning behavior.
tumor-bearing mice with ZnSO4 increased hepatic, renal and tumor 
MT  and  protected  them  from  cytotoxic  actions  of  cisplatin.35  It 
is important to note that MT-I, II are powerful scavengers of free 
radicals, likely as a function of their cysteine residues.30 In addition, 
it was concluded that MT induction creates a new pool of thiol 
groups in the cell cytosol that can attenuate damaging effects of 
GSH depletors in rat hepatocytes.65 Further studies indicated that 
the released Zn+2 from MT might suppress free radical-mediated 
damage  by  its  ability  to  induce  the  metalloenzyme  superoxide 
dismutase or to stabilize the cell membrane function.66 In addition, 
it has been shown MT induced by zinc exhibited protective effects 
from doxorubicin-induced myocardial apoptosis36 and adriamycin-
induced myocardial injury by inhibition of oxidative stress-mediated 
mitochondrial cytochrome c release and caspase-3.38 On the other 
hand,  the  oxidative  stress-dependent  pathway  for  increased  levels 
of TNFα  and  other  cytokines  and  their  implication  in  neuronal 
injury has been reported.30,51 MT-I, II were reported to inhibit the 
expression of proinflammatory cytokines such as interleukins IL-1β, 
IL-6, IL-12 and TNFα with subsequent suppression of the inflam-
matory  responses  of  leukocytes.30  It  was  found  that  exogenous 
administration of metallothionein reduced pro-inflammatory cytok-
ines IL-6 and TNFα and apoptotic cell death during experimental 
autoimmune  encephalomyelitis.67  Herein,  it  could  be  proposed 
that  among  the  key  mechanisms  for  improvement  of  BCNU-
induced  learning  and  memory  deficits  after  induction  of  brain 
MT  by  administration  of  ZnSO4  is  the  buffering  effect  of  MT 
against BCNU-induced hippocampal damage through rebalancing 
of  oxidant/antioxidant  equilibrium  (as  the  levels  of  GR  activity 
and GSH content were preserved), anti-inflammatory effect (as the 
level of TNFα was markedly reduced) and antiapoptotic effect (as it 
produced marked reduction in caspase-3 activity).
In conclusion, the obtained data may suggest that MT induc-
tion can act against BCNU-induced hippocampal cognitive deficits. 
This effect is mediated at least in part by antioxidant, antiapoptotic 
and anti-inflammatory mechanisms as well as maintenance of zinc 
homeostasis. This may help to understand the role of metallothi-
onein in chemotherapy-induced neurocognitive dysfunction which 
may be considered for the improvement of behavioral pattern during 
administration of anticancer agents.
Methods
Animals. Adult male Wistar albino rats weighing 150–180 g were 
obtained from the Animal Care Center, College of Pharmacy, King 
Saud University, Riyadh, Saudi Arabia. The animals were housed in 
metabolic cages under standard laboratory conditions (12 h light/
dark cycle at 25 ± 2°C) with free access to pulverized standard rat 
pellet food and tap water.
Experimental  protocol.  A total of 60 male Wistar albino rats 
were randomly divided into four groups (15/group): The first group 
served as a control group in which the animals received a single 
intracerbrovenricular (i.c.v) dose of normal saline (10 μl) followed 
24 h later with an i.v injection of BCNU solvent (normal saline 
containing 10% ethanol). The second group administered a single 
dose of ZnSO4 (0.1 μmol/10 μl normal saline, i.c.v) followed 24 h 
later  with  an  injection  of  BCNU  solvent  (i.v).  Rats  in  the  third 
group received a single dose of BCNU (20 mg/kg, i.v) 24 h after an   Metallothionein in memory impairement
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1,750 μl of 0.1 M potassium phosphate buffer (pH 8) and 50 μl of 
5,5 dithiobis-2-nitrobenzoic acid (DTNB) reagent. The tubes were 
mixed and the developed yellow color was measured against stan-
dard curve of reduced glutathione. Protein thiols (protein-SH) were 
expressed as μmol/g tissue.
Determination  of  serum  TNFα.  Serum  TNFα,  was  assayed 
by using ELISA kit purchased from R&D Systems (Minneapolis, 
MN, USA) according to the protocol provided by the manufacturer. 
Briefly, in a microplate, 50 μl of the assay diluent added to each well. 
Then 50 μl of the diluted serum sample (2-fold dilution in the cali-
brator diluent) were added to each well and mixed gently by tapping 
the plate frame for 1 min then the plate was covered and incubated 
for 2 h at room temperature. After incubation, each well in the plate 
was then aspirated and washed five times with the kit washing buffer 
followed by addition of 100 μl substrate solution and incubated in 
dark for 30 min at room temperature. The optical density was then 
read at 450 nm using a 96-well plate spectrometer (Spectra Max 190, 
Molecular Devices Corp., Sunnyvale, CA, USA). TNFα level (pg/ml) 
was calculated from a standard curve and multiplied by the dilution 
factor.
Determination of hippocampal caspase-3 activity. Hippocampal 
cell  suspension  was  prepared  from  hippocampal  tissue  following 
the method described by Sameto.72 Briefly, hippocampi from each 
animal were dissected out, cut into small pieces and suspended in 10 
mL sterile saline solution (12.38 mmol/L NaCl, 5.4 mmol/L KCl, 
1.1 mmol/L Na2HPO4, 1.1 mmol/L KH2PO4, 22 mmol/L glucose 
and 0.9 CaCl2), containing 0.25% v/v trypsin, in a Petri dish. The 
suspension was then aspirated two to three times using glass pipette 
and transferred to a screw-capped Erlenmeyer flask and shaken on a 
rotary shaker (80 r.p.m. for 15 min at 37°C). Trypsinization was then 
halted by the addition of 10 mL serum supplemental medium (SSM) 
containing 10% v/v fetal bovine serum (FBS) and the disrupted tissue 
was then gently aspirated three times using a 10 ml glass pipette. The 
aspirated suspension was carefully filtered through Nitex 210 then 
Nitex 130 filters (TetKo, Elmeford, NY, USA) by gravity. The entire 
filtrate was then centrifuged at 800 g for 5 min at room temperature 
and the pellet was resuspended in fresh SSM. Viable cells were counted 
using a haemocytometer and trypan blue 0.4% diluted in phosphate-
buffered saline (PBS) containing 1 mmol/L EDTA (1:16).
Hippocampal caspase-3 activity was measured by using Caspase-3/
CPP32 activity Colorimetric Assay Kit (Biovision Incorporate, USA) 
according the procedure supplied by the manufacturer. Briefly, the 
prepared cell suspension was centrifuged. Then cells were resuspended 
in chilled cell lysis buffer (1–5 x 106 cells/50 μl) and incubated on 
ice for 10 min, centrifuged for 1 min in a microcentrifuge (10,000 
xg). To each sample pellet, 50 μl cell lysis buffer was added followed 
by  addition  of  50  μl  of  2X  reaction  buffer  (containing  10  mM 
DTT).  5  μl  of  the  4  mM  DEVD-pNA  substrate  (200  μM  final 
conc.) was added and to each sample and incubated at 37°C for 2 h. 
Samples were read at 405-nm in a microtiter plate ELISA reader. 
The absorbance of the produced color (pNA) from treated animals 
was compared with control animals to determinate the percentage of 
caspase-3 activity changes.
Determination of hippocampal MDA. Hippocampal lipid perox-
ides  were  determined  colorimetrically  using  thiobarbituric  acid 
(TBA), as described by Uchiyama and Mihara,73 where lipid peroxides 
Histological  examination  and  immunohistochemical  staining 
for brain MT. Rats were anaesthetized with ether and brains were 
dissected out on ice and fixed in 10% formalin saline solution then 
embedded in paraffin. The 5 μm sections were stained on glass slides 
by Hx & E and examined under light microscope for histological 
alterations in the hippocampus. The mean number of 10 microscopic 
fields of normally-appeared hippocampal neurons was calculated.
Expression of brain MT was evaluated by immunohistochemical 
staining of brain tissues using monoclonal mouse anti-MT antibody 
(Dako,  Carpentaria,  CA,  USA)  and  vectastain  ABC  kit  (Vector 
Laboratories, Burlingame, CA, USA). After deparaffinization, brain 
sections on glass slides were subjected to quenching of endogenous 
peroxidase activity using 3% H2O2 for 10 min at room tempera-
ture. Non-specific binding sites were blocked by 5% normal rabbit 
serum for 1 h, then washed with PBS buffer for 10 min. Sections 
were incubated with primary MT antibodies (diluted 1:500 in 10 
mmol/L PBS) overnight at 4°C and then washed with PBS buffer 
for 10 min. Sections were incubated with biotinylated rabbit anti-
mouse Ig G (secondary antibodies) for 1 h and then washed with 
PBS buffer for 10 min, followed by the addition of vectastain ABC 
reagent and incubation for 1 h, with a final wash using PBS buffer. 
The  substrate  solution  in  the  kit,  diaminobenzedine  (DAB),  was 
added and the color was produced within 2–7 min. Stained sections 
were washed under tap water, air dried and photographed under a 
light microscope.
Determination of hippocampal MT. Hippocampal content of 
MT was measured by ELISA.23 Briefly, in a microtiter plate, 150 μl 
of 10% tissue homogenate from each sample in coating buffer (0.015 
M Na2CO3, 0.023 M NaHCO3, 0.02% Na azide in 80 ml H2O, pH 
9.8) added to the wells and left at 4°C overnight. The wells were then 
washed three times with phosphate buffered saline (PBS) solution 
containing 1% Tween (pH, 7.4). To each well 150 μl of MT primary 
antibodies (diluted 1:500 in PBS-Tween solution) and incubated on 
a shaker for 2 h. Anti-mouse Ig G secondary antibodies diluted in 
PBS-Tween were added (150 μl/well) and the plate was incubated 
at room temperature for 2 h followed by washing of the wells with 
PBS-Tween three times. The substrate solution (p-nitrophenol) was 
added (150 μl/well) and incubated in dark at room temperature for 
30 min. The reaction was stopped by addition of 50 μl 3N NaOH 
solution to each well. The absorbance of produced color was read at 
405 nm in ELISA reader where MT concentration (μg/g protein) 
was calculated from a standard calibration curve of MT protein.
Determination of hippocampal GR activity and GSH content. GR 
activity was measured by the method of Carlberg and Mannervick.70 
Briefly, 100 μl of 0.2 M sodium phosphate, pH 7.6 (containing   
1 mM EDTA), 25 μl 20 mM GSSG and 25 μl 2 mM NADPH were 
incubated at 30°C for 10 min. 50 μl of 5% hippocampus homoge-
nate sample (in 50 mmol/L phosphate buffer, pH 7.0 containing 
0.1 mmol/L EDTA) were added into a reaction cuvette, and the rate 
of change of absorbance at 340 nm was measured for 3 min. The 
activity of GR was expressed as mU/mg protein.
Tissue levels of acid soluble thiols, mainly reduced glutathione 
(GSH), were determined calorimetrically at 412 nm according to 
Ellman.7 In briefl, 0.5 ml of previously prepared homogenate was 
added to 0.5 ml of 5% trichloroacetic acid, centrifuged at 1,000 xg 
for 5 min. The supernatant (200 μl) was added to a tube contains Metallothionein in memory impairement
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expressed  in  terms  of  MDA  concentration  (nmol/mg  protein). 
In  brief,  hippocampus  lobes  were  homogenized  separately  in  50 
mmol/L phosphate buffer (pH 7.0) containing 0.1 mmol/L EDTA 
to obtain a 5% homogenate. In a Teflon-stoppered test tube, 2.5 ml 
of 20% acetic acid and 1 ml TBA solution were added to the tissue 
homogenate and allowed to boil at 100°C for 30 min in a water bath. 
After cooling to room temperature under tap water, 4 ml n-butanol 
was added and samples were shaken vigorously and centrifuged at 
600 g for 5 min. The absorbance of the upper colored layer was 
measured at 532 nm and the concentration of MDA was calculated 
from a standard calibration curve and expressed as nmol/g protein.
Total protein assay. Total protein was determined according to 
the method of Lowery et al.74 In brief, 1.0 ml of alkaline copper solu-
tion (prepared by mixing 50 ml of 2% Na2CO3 in 0.10 N NaOH 
with 1.0 ml of 0.50% CuSO4. 5 H2O in 1% sodium tartrate) was 
added to a test tube containing 0.20 ml of 10% hippocampus homo-
genate (w/v), mixed well and allowed to stand for 10 min at room 
temperature. Then, 0.10 ml of Folin’s reagent (phospho-molybdic-
phosphotungstic reagent diluted 1:1 in H2O before use) was added 
and thoroughly mixed. After 30 min the optical density was measured 
against blank at 500 nm. Protein concentration was calculated from 
a standard calibration curve in which bovine albumin was used in 
different concentrations.
Statistical analysis. Data were presented as mean ± SEM and 
analyzed  using  Graph  Pad  Instat  software  by  one  way  ANOVA 
followed by Tukey Kramer post-test at p < 0.05.
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